sddt.com
Stephen Chang of Canji Inc.
Source: Canji Inc.
Stephen M.W. Chang joined Canji Inc. in January 1998 as chief scientific officer and vice president of Schering-Plough Research Institute. Canji Inc. is a wholly owned subsidiary of Schering-Plough Corp. (Nasdaq: SGP) of New Jersey and is Schering-Plough's "Center of Excellence for Gene Therapy" based in San Diego.
Prior to joining Canji, Chang was director of research for Chiron Inc. (Nasdaq: CHIG), having served in positions of increasing responsibility from 1988 to 1998.
Chang obtained a triple major bachelor's of science in zoology, microbiology and cell & molecular biology (cum laude) from University of Michigan 1977, and received his doctorate in the Departments of Biological Chemistry and Molecular Biology & Biochemistry from University of California, Irvine in 1983.
Chang's main scientific areas of interest are in gene transfer applications and technologies, gene regulation, HIV molecular virology, hepatitis molecular virology, viral cellular immune responses, human genetics, functional genomics, cancer gene therapy, and orchid genetics and cell biology.
In this regard, Chang is, and has been for several years, very active on advisory boards, editorial boards, study sections and industrial liaison committees in the areas of gene therapy, HIV, AIDS, Hemophilia and Mental Health for such organizations as National Cancer Institute, National Institutes of Health, National Institute of Mental Health, Massachusetts Institute of Technology and American Society of Gene Therapy.
In 2002, Chang served as a board member for the California Healthcare Institute and is a newly elected board member for Biocom/San Diego. |
